For Immediate Release
Chicago, IL – April 23, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PayPal (PYPL - Free Report) , International Business Machines (IBM - Free Report) , Fresenius Medical Care (FMS - Free Report) , Laboratory Corp. of America (LH - Free Report) and Insulet (PODD - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for PayPal, IBM and Fresenius Medical
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PayPal, International Business Machines and Fresenius Medical Care. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
PayPal’s shares have outperformed the Zacks Internet Software industry over the past six months (+15.6% vs. +7.7%). The Zacks analyst believes that PayPal’s portfolio strength remains its key catalyst. Venmo’s improving monetization efforts and rising adoption rate across various platforms are aiding total active accounts.
Further, robust mobile checkout services of One Touch are contributing to the company’s total payment volume growth. Growing momentum across core peer to peer is also aiding in acceleration of payment volume. Additionally, the company is benefiting from well-performing core PayPal and Braintree. Positive contributions from Hyperwallet buyout are tailwinds.
However, eBay’s managed payments transition remains a concern. Moreover, declining eBay volume remains a headwind for the company’s TPV. Moreover, PayPal anticipates Honey and GoPay buyouts to limit earnings growth in 2020.
Shares of IBM have lost -14.9% over the past year against the S&P 500’s fall of -7.2%. The Zacks analyst believes that growing clout of Watson Health and growth in Payer, Provider, Imaging and Life Sciences verticals are noteworthy. Also, gains from z15 hold promise.
IBM’s Q1 earnings and revenues declined year over year. Notably, adoption of cognitive applications and transaction processing platforms in March was affected by the coronavirus outbreak. For 2020, IBM has withdrawn guidance, citing uncertainty pertaining to coronavirus crisis.
Nevertheless, improving position in the hosted cloud, security and analytics domains bodes well. Moreover, Red Hat acquisition has helped IBM to enhance containerized software capabilities and strengthen competitive position in the hybrid cloud market. However, stiff competition in the cloud computing market and high-debt levels remain woes.
Fresenius Medical’s shares have lost -6.7% over the past three months against the Zacks Medical Instruments industry’s fall of -10.5%. The Zacks analyst believes that Fresenius Medical continues to gain from core Health Care Products and Services segments, which witnessed revenue growth in the quarter under review.
Revenues in the North American, EMEA and Asia-Pacific regions also improved. In fact, management remains optimistic about the buyouts of Sound Physicians and NxStage Medical. Furthermore, strong view for 2020 portrays a brighter picture. A wide range of dialysis products and services instills optimism in the stock.
Management expects to undertake meaningful investments in 2020 to capitalize on opportunities and optimize cost base. The company reported strong results in the fourth quarter. However, an intensely competitive dialysis products market and global coronavirus outbreak have added to woes.
Other noteworthy reports we are featuring today include Laboratory Corp. of America and Insulet.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.